Rebecca C.E. McFadyen, Ph.D.

Matters

Advised a state university and its research foundation in a patent infringement suit against multiple pharmaceutical companies involving various products.
Handled complex matters involving cardiovascular and cardiopulmonary medical devices for a multinational medical device corporation.
Evaluated scientific and medical information for hernia mesh manufacturer in a high-profile MDL.

Firm Highlights

Slide 1 of 6

Publication
The Politics of AI Regulation: Federal Government v. the States
On December 11, 2025, President Trump signed Executive Order 14365, “Ensuring a National Policy Framework for Artificial Intelligence.”
Read more
Event
Polsinelli Pulse Series: Shelf Space – Strategies for Dominating the CPG Marketplace
Join Polsinelli as we speak with investors in, and founders of, your favorite CPG brands, to learn what they’ve done right, what they’ve done wrong, and what they’re still trying to figure out.
Read more
Blog
Where Identity Meets Precedent: The EEOC Addresses Bathroom and Locker Room Access Under Title VII
Read more
News
Polsinelli Advises Americana Partners on Acquisition of NRT Consulting
Polsinelli recently represented Americana Partners (Americana), a Houston-based wealth management firm, in its acquisition of NRT Consulting, a bespoke and full-service financial consulting and accounting firm.
Read more
News
Polsinelli Secures Dismissal of Data Breach Class Action for Delta Health
Polsinelli recently secured a significant win for firm client Delta County Memorial Hospital District (Delta Health), obtaining dismissal of a putative data breach class action in the District Court for Delta County, Colorado.
Read more
Publication
Not Joking Around: FDA Offers Additional Clarification on Compounded GLP-1 Policy in April Fool’s Day Announcement
FDA's April 1, 2026, update to its compounding policy page follows more than 18 months of regulatory activity surrounding the compounding of GLP-1 medications.
Read more